Abstract
Objectives-To evaluate the use of polymorphic DNA probes linked to the APC gene in the presymptomatic diagnosis of familial adenomatous polyposis.
Design-Four DNA probes were tested on an unselected population of patients at risk of familial adenomatous polyposis.
Subjects-The first 47 families notified to the West Midlands familial adenomatous polyposis register. Plus five families sent to our hospital as part of the West of Britain DNA consortium.
Main outcome measures-The proportion of families and family members in whom DNA testing could be used to adjust the estimate of risk.
Results-Only 17 families on the register (containing 46% (74/162) of the population at risk) had a suitable pedigree structure for DNA analysis. DNA was analysed in 12 of these families plus the five families from the West of Britain consortium. At least one probe was informative in 27 of the 33 subjects born with 50% risk, but the most informative probe (n227) was the one with the highest recombination rate (10%). Flanking markers were informative in only four of the 33 subjects.
Conclusions -These findings confirm the potential for accurate predictive diagnosis of familial adenomatous polyposis with polymorphic DNA probes, but such an approach is currently limited to about one third of affected families. A combined approach to presymptomatic diagnosis, which includes DNA testing and indirect ophthalmoscopy, is advocated.
Introduction
Familial adenomatous polyposis is an autosomal dominant condition which shows almost complete penetrance and occurs at a frequency of 1 The DNA of 42 affected subjects was analysed to determine if the probes would be informative for presymptomatic diagnosis in their children. At least one of the probes was informative in 40 affected subjects, but in 25 the only informative probe was :r227. Flanking markers were informative in slightly less than half the affected individuals (table III) .
The 12 families from the West Midlands register with suitable pedigrees for DNA analysis contained 54 subjects born with 50% risk of developing familial adenomatous polyposis. Eighteen of these were under 10 years of age, below the age at which bowel screening would be initiated, and thus were not screened; four subjects were over 50 years old and asymptomatic so again DNA testing was not done. Of the remaining 32 subjects, 28 were tested together with five subjects from the West of Britain families. The four untested subjects comprised two (from one family) whose parents refused screening, one who was being screened at another centre, and one (14 year old) in whom screening was postponed at parental request. Presymptomatic diagnosis was possible with at least one probe in 27 subjects at risk and again the most informative probe was 7u227 (66%). Flanking markers were informative in only four of the subjects at risk (table III) . Table IV gives the risk before and after analysis in BMJ VOLUME 304 (fig 1), of no value (fig 2)  and impossible to perform (fig 3) . Figure 1 shows a family in whom cr227 was fully informative. The disease in this family segregates with allele 3 so in the two people at risk (IV-C and IV-E) the risk is independently reduced to 10% on the basis of the DNA results. As neither IV-C nor IV-E had congenital hypertrophy of the retinal pigment epithelium and both had negative results on recent sigmoidoscopy, the combined risk that these two people will be affected, is less than 1%. 16 By contrast, in figure 2 the two people at risk (II-D and II-E) remain at 50% risk as their affected father (I-C) was homozygous for all probes and no member of the family had any evidence of congenital hypertrophy of the retinal pigment epithelium. In figure 3 no DNA testing could be carried out because the key affected family members had died before storage of DNA.
Discussion
Several studies have shown the potential value of probes linked to the APC gene for presymptomatic diagnosis of familial adenomatous polyposis.'°" Our study highlighted several practical problems which limit DNA analysis for predictive diagnosis in all affected families, some of which do not seem to have been considered before. In particular we found that DNA testing was impossible in over half of the families with familial adenomatous polyposis, either because the disease was caused by a new mutation or because relevant affected family members were dead.
Even with increasingly early surgical intervention and more rigorous screening protocols, early death from colorectal cancer still occurs. As a consequence only 35% of our families were suitable for linkage analysis. These In linkage analysis the possibility of genetic heterogeneity must always be considered. This is the possibility that a mutation in two different genes can give rise to the same clinical phenotype. The number of families with familial adenomatous polyposis studied worldwide is still relatively small, and although as yet there is no evidence of genetic heterogeneity, it cannot be ruled out. '7 For example, in adult polycystic kidney disease there was no initial evidence of heterogeneity, but after five years of using probes linked to the PKD 1 locus for presymptomatic diagnosis, evidence for a second locus has been found.74 Therefore bowel screening should not be stopped completely, even in people predicted to be at very low risk based on DNA results. Instead, additonal tests are needed that can be used to complement the DNA studies.
At the present time, a combined approach to the investigation of affected families would seem to be most appropriate. This approach includes the notification of families to a register, sigmoidoscopy as appropriate, examination by indirect ophthalmoscopy for congenital hypertrophy of retinal pigment epithelium, identification of other extra colonic signs, and family studies with DNA probes. At this time we would advocate using predictive diagnosis only once bowel screenng has been started. However, now that the APC gene has been identified, the future possibility of presymptomatic interventional therapy may alter this approach.
An integrated approach to screening families with familial adenomatous polyposis is now available. This enables high risk family members to be identified and encouraged to attend for frequent bowel screening. Less frequent screening can be offered to those found to be at low risk. This should help to improve compliance with bowel screening and so further reduce the incidence of colorectal cancer in these families.
Glossary
Polymorphic markers-Markers (for example C lIp1 1) that recognise fragments of variable size. At 
